Therapy News and Research

RSS

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

Excess EXO1 protein may drive cancer DNA damage and treatment response

When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells.

21 May 2026

Study supports routine childhood screening for type 1 diabetes

For ten years, the Fr1da study, coordinated by Helmholtz Munich, has been investigating whether early stages of type 1 diabetes in children can be detected in routine pediatric care.

21 May 2026

Scientists capture immune cells attacking live melanoma cells in real time

Scientists at the Garvan Institute of Medical Research have captured, for the first time, 'housekeeping' immune cells actively attacking and engulfing live melanoma cells – a discovery that could change the way we approach treatment for one of Australia's most common and deadly cancers.

21 May 2026

Experimental virus therapy targets resistant high-grade neuroendocrine tumors

A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors that often resist treatment.

21 May 2026

Artificial intelligence-based tool could improve multiple myeloma treatment decisions

An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.

21 May 2026

Specific gene fusion patterns tied to solitary fibrous tumor outcomes

Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve how physicians assess and eventually treat this rare cancer.

21 May 2026

Vitamin B12 analog targets deadly brain cancer cells

A new research paper was published in Volume 13 of Oncoscience on April 2, 2026, titled "Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide."

21 May 2026

Researchers discover how overpopulation reduces fertility

Scientists have reported it for decades: Overpopulation can impair reproduction.

21 May 2026

New immuno-infrared sensor aids in early diagnosis of Alzheimer’s and Parkinson’s disease

An early start to treatment is crucial to successful therapy. A new sensor is helping with early detection.

21 May 2026

Machine learning lifestyle coaching helps reduce major depressive symptoms

More than 21% of U.S. adults experience depression, greatly impacting their quality of life. Many people with mild‑to‑moderate depression can improve their symptoms by adjusting daily habits like sleep, exercise, diet and social interaction, according to Jyoti Mishra, PhD, associate professor of psychiatry at University of California San Diego School of Medicine.

21 May 2026

HonorHealth Research Institute tests steam therapy for diabetes treatment

HonorHealth Research Institute is looking to become the first research facility in the nation to begin a new clinical trial that aims to modify the lining of the digestive tract with the use of steam energy to control type II diabetes without the use of drugs.

21 May 2026

Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment. In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 (FGF23), a hormone that causes phosphate loss through the kidneys.

21 May 2026

Small T-cell subset drives powerful multiple myeloma immunotherapy responses

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

21 May 2026

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

The nanomotor starts with bowl‑shaped mesoporous polydopamine (PDA) nanoparticles. These biocompatible bowls are loaded with two key payloads: Fe(II) ions as a Fenton catalyst, and BNN6, a thermally sensitive NO donor.

21 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026

Evaluating stroke-prevention strategies in patients with atrial fibrillation by age

The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide.

20 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Most college students with psychosis lack recommended combination treatment

Although the majority of students sought and received therapy or counseling in the past 12 months, less than 40 percent received the recommended combination of therapy/counseling and antipsychotic medication, suggesting potential barriers to accessing this medication.

20 May 2026